154 related articles for article (PubMed ID: 1607535)
1. Heparin-induced prolongation of partial thromboplastin time after thrombolysis: relation to coronary artery patency. HART Investigators.
Hsia J; Kleiman N; Aguirre F; Chaitman BR; Roberts R; Ross AM
J Am Coll Cardiol; 1992 Jul; 20(1):31-5. PubMed ID: 1607535
[TBL] [Abstract][Full Text] [Related]
2. Correlation between level of heparinization and patency of the infarct-related coronary artery after treatment of acute myocardial infarction with alteplase (rt-PA).
Arnout J; Simoons M; de Bono D; Rapold HJ; Collen D; Verstraete M
J Am Coll Cardiol; 1992 Sep; 20(3):513-9. PubMed ID: 1512327
[TBL] [Abstract][Full Text] [Related]
3. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial.
Cannon CP; McCabe CH; Henry TD; Schweiger MJ; Gibson RS; Mueller HS; Becker RC; Kleiman NS; Haugland JM; Anderson JL
J Am Coll Cardiol; 1994 Apr; 23(5):993-1003. PubMed ID: 8144799
[TBL] [Abstract][Full Text] [Related]
4. Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction.
Bleich SD; Nichols TC; Schumacher RR; Cooke DH; Tate DA; Teichman SL
Am J Cardiol; 1990 Dec; 66(20):1412-7. PubMed ID: 2123602
[TBL] [Abstract][Full Text] [Related]
5. A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. Heparin-Aspirin Reperfusion Trial (HART) Investigators.
Hsia J; Hamilton WP; Kleiman N; Roberts R; Chaitman BR; Ross AM
N Engl J Med; 1990 Nov; 323(21):1433-7. PubMed ID: 2122251
[TBL] [Abstract][Full Text] [Related]
6. Sequential combination thrombolytic therapy for acute myocardial infarction: results of the Pro-Urokinase and t-PA Enhancement of Thrombolysis (PATENT) Trial.
Zarich SW; Kowalchuk GJ; Weaver WD; Loscalzo J; Sassower M; Manzo K; Byrnes C; Muller JE; Gurewich V
J Am Coll Cardiol; 1995 Aug; 26(2):374-9. PubMed ID: 7608437
[TBL] [Abstract][Full Text] [Related]
7. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction.
GUSTO Angiographic Investigators
N Engl J Med; 1993 Nov; 329(22):1615-22. PubMed ID: 8232430
[TBL] [Abstract][Full Text] [Related]
8. Randomized double-blind comparison of two doses of Hirulog with heparin as adjunctive therapy to streptokinase to promote early patency of the infarct-related artery in acute myocardial infarction.
Théroux P; Pérez-Villa F; Waters D; Lespérance J; Shabani F; Bonan R
Circulation; 1995 Apr; 91(8):2132-9. PubMed ID: 7697841
[TBL] [Abstract][Full Text] [Related]
9. High dose bolus heparin as initial therapy before primary angioplasty for acute myocardial infarction: results of the Heparin in Early Patency (HEAP) pilot study.
Verheugt FW; Liem A; Zijlstra F; Marsh RC; Veen G; Bronzwaer JG
J Am Coll Cardiol; 1998 Feb; 31(2):289-93. PubMed ID: 9462569
[TBL] [Abstract][Full Text] [Related]
10. Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trial.
Cannon CP; McCabe CH; Diver DJ; Herson S; Greene RM; Shah PK; Sequeira RF; Leya F; Kirshenbaum JM; Magorien RD
J Am Coll Cardiol; 1994 Dec; 24(7):1602-10. PubMed ID: 7963104
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of 100 mg of double-bolus alteplase in achieving complete perfusion in the treatment of acute myocardial infarction.
Purvis JA; McNeill AJ; Siddiqui RA; Roberts MJ; McClements BM; McEneaney D; Campbell NP; Khan MM; Webb SW; Wilson CM
J Am Coll Cardiol; 1994 Jan; 23(1):6-10. PubMed ID: 8277097
[TBL] [Abstract][Full Text] [Related]
12. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial.
Bovill EG; Terrin ML; Stump DC; Berke AD; Frederick M; Collen D; Feit F; Gore JM; Hillis LD; Lambrew CT
Ann Intern Med; 1991 Aug; 115(4):256-65. PubMed ID: 1906692
[TBL] [Abstract][Full Text] [Related]
13. Improved thrombolysis in acute myocardial infarction with front-loaded administration of alteplase: results of the rt-PA-APSAC patency study (TAPS).
Neuhaus KL; von Essen R; Tebbe U; Vogt A; Roth M; Riess M; Niederer W; Forycki F; Wirtzfeld A; Maeurer W
J Am Coll Cardiol; 1992 Apr; 19(5):885-91. PubMed ID: 1552106
[TBL] [Abstract][Full Text] [Related]
14. Thrombolysis with recombinant unglycosylated single-chain urokinase-type plasminogen activator (saruplase) in acute myocardial infarction: influence of heparin on early patency rate (LIMITS study). Liquemin in Myocardial Infarction During Thrombolysis With Saruplase.
Tebbe U; Windeler J; Boesl I; Hoffmann H; Wojcik J; Ashmawy M; Rüdiger Schwarz E; von Loewis P; Rosemeyer P; Hopkins G
J Am Coll Cardiol; 1995 Aug; 26(2):365-73. PubMed ID: 7608436
[TBL] [Abstract][Full Text] [Related]
15. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. GUSTO-I Investigators.
Simes RJ; Topol EJ; Holmes DR; White HD; Rutsch WR; Vahanian A; Simoons ML; Morris D; Betriu A; Califf RM
Circulation; 1995 Apr; 91(7):1923-8. PubMed ID: 7895348
[TBL] [Abstract][Full Text] [Related]
16. Randomized comparison of enoxaparin, a low-molecular-weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin: second trial of Heparin and Aspirin Reperfusion Therapy (HART II).
Ross AM; Molhoek P; Lundergan C; Knudtson M; Draoui Y; Regalado L; Le Louer V; Bigonzi F; Schwartz W; de Jong E; Coyne K;
Circulation; 2001 Aug; 104(6):648-52. PubMed ID: 11489769
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of streptokinase, but not tissue-type plasminogen activator, in achieving 90-minute patency after thrombolysis for acute myocardial infarction decreases with time to treatment. PERM Study Group. Prospective Evaluation of Reperfusion Markers.
Steg PG; Laperche T; Golmard JL; Juliard JM; Benamer H; Himbert D; Aubry P
J Am Coll Cardiol; 1998 Mar; 31(4):776-9. PubMed ID: 9525545
[TBL] [Abstract][Full Text] [Related]
18. Gender and acute myocardial infarction: is there a different response to thrombolysis?
Woodfield SL; Lundergan CF; Reiner JS; Thompson MA; Rohrbeck SC; Deychak Y; Smith JO; Burton JR; McCarthy WF; Califf RM; White HD; Weaver WD; Topol EJ; Ross AM
J Am Coll Cardiol; 1997 Jan; 29(1):35-42. PubMed ID: 8996292
[TBL] [Abstract][Full Text] [Related]
19. Patency trials with reteplase (r-PA): what do they tell us?
Bode C; Nordt TK; Peter K; Smalling RW; Runge MS; Kübler W
Am J Cardiol; 1996 Dec; 78(12A):16-9. PubMed ID: 8990406
[TBL] [Abstract][Full Text] [Related]
20. ESPRIT: a European study of the prevention of reocclusion after initial thrombolysis with duteplase in acute myocardial infarction.
Malcolm AD; Keltai M; Walsh MJ
Eur Heart J; 1996 Oct; 17(10):1522-31. PubMed ID: 8909909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
